Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Micro-TESE & Sperm Retrieval

Microdissection Testicular Sperm Extraction (Schlegel technique)

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Surgical procedure (not an FDA product category)

Reference only. Not medical advice.

What can go wrong

It is a microsurgical procedure under anesthesia with risks of hematoma, infection, pain, and a transient or, less commonly, persistent decline in testosterone from tissue removal. Retrieval can fail entirely (no sperm found), and repeat procedures have lower yields. Counseling on realistic, diagnosis-specific success rates is essential before surgery.

This is something to take to a clinician. The Atlas can tell you what is known about micro-tese & sperm retrieval in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Microdissection TESE, the technique described by Peter Schlegel, is the gold-standard surgical retrieval for non-obstructive azoospermia (NOA). Using an operating microscope, the surgeon opens the testis and identifies the larger, more opaque seminiferous tubules most likely to contain sperm, sparing tissue and blood supply versus conventional TESE. Retrieved sperm are used with ICSI. Overall NOA retrieval rates cluster around 40-60%, varying sharply by underlying diagnosis and histology.

Finding sperm where ejaculate has none, under the microscope, tubule by tubule.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Sperm retrieval in non-obstructive azoospermia
  • Klinefelter syndrome retrieval
  • Retrieval after chemotherapy or cryptorchidism
  • Salvage retrieval after failed conventional TESE

How it works

Under high magnification, the surgeon distinguishes dilated, opaque tubules (which more often contain active spermatogenesis) from thin, sclerotic ones, excising only small targeted samples. This raises the chance of finding rare focal spermatogenesis while minimizing tissue removal, devascularization, and androgen-producing tissue loss compared with random multi-biopsy TESE.

Retrieval rates depend heavily on the diagnosis

Reported sperm retrieval rates by NOA etiology in published series vary widely but illustrate the spread: cryptorchidism and prior orchitis often retrieve well (frequently 60-90% in some series), AZFc Y-chromosome microdeletions and chromosomal anomalies fall in the middle (roughly 50-60%), while idiopathic NOA and Sertoli-cell-only patterns are lower (often ~25-40%). Histology is among the strongest predictors, hypospermatogenesis yields very high success, maturation arrest intermediate, and Sertoli-cell-only the lowest. These figures are series-specific and should be read as ranges, not guarantees.

What people get wrong

  • Often saidAzoospermia means no chance of biological fatherhood

    ActuallyIn non-obstructive azoospermia, micro-TESE retrieves usable sperm in a meaningful fraction of men, overall often 40-60%, enabling ICSI. The chance depends on the cause.

  • Often saidMore tissue removed means better odds

    ActuallyMicro-TESE improves yield precisely by removing less but targeting better. Random extensive biopsy risks testosterone loss without improving sperm yield.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

Compared with conventional TESE (random biopsies) and TESA/PESA (needle aspiration, mainly for obstructive cases), micro-TESE offers higher retrieval in NOA with less tissue loss, at the cost of a longer microsurgical procedure requiring specialized expertise.

At a glance

Originator
Peter Schlegel (technique standardized in the late 1990s)
Primary indication
Non-obstructive azoospermia
Overall NOA retrieval
Commonly ~40-60% (study-dependent)
Downstream use
Sperm paired with ICSI

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Micro-TESE & Sperm Retrieval. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Schlegel microdissection TESE technique1999

    Described microscope-guided tubule selection, improving retrieval and reducing tissue removal versus conventional TESE

  • NOA retrieval by etiology (multiple series, e.g., PMC11430832)various

    Reported retrieval rates differing by cause: e.g., cryptorchidism ~69%, Klinefelter ~42%, idiopathic ~28%, orchitis ~90% in one analysis

  • Histology as predictor (multiple series)various

    Hypospermatogenesis ~94% retrieval; maturation arrest ~43%; Sertoli-cell-only ~37%